Beyond Docetaxel: Targeting Resistance Pathways in Prostate Cancer Treatment
Prostate cancer continues to be the most common cause of cancer-related disease and mortality among men worldwide, especially in the advanced stages, notably metastatic castration-resistant prostate cancer (mCRPC), which poses significant treatment challenges. Docetaxel, a widely used chemotherapeut...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2025-08-01
|
| Col·lecció: | BioChem |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2673-6411/5/3/24 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|